Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis

F. Paulina Núñez, Noa Krugliak Cleveland, Rodrigo Quera, David T. Rubin*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Inflammatory bowel disease, encompassing Crohn's disease (CD) and ulcerative colitis, are chronic immune-mediated inflammatory bowel diseases (IBD) that primarily affect the gastrointestinal tract with periods of activity and remission. Large body of evidence exist to strengthen the prognostic role of endoscopic evaluation for both disease activity and severity and it remains the gold standard for the assessment of mucosal healing. Mucosal healing has been associated with improved clinical outcomes with prolonged remission, decreased hospitalization, IBD-related surgeries and colorectal cancer risk. Therefore, endoscopic objectives in IBD have been incorporated as part of standard care. With the known increased risk of colorectal cancer in IBD, although prevention strategies continue to develop, regular surveillance for early detection of neoplasia continue to be paramount in IBD patients' care. It is thanks to evolving technology and visualization techniques that surveillance strategies are continuously advancing. Therapeutic endoscopic options in IBD have also been expanding, from surgery sparing therapies such as balloon dilation of fibrostenotic strictures in CD to endoscopic mucosal resection of neoplastic lesions. In this review article, we discuss the current evidence on the use of endoscopy as part of standard of care of IBD, its role in surveillance of neoplasia, and the role of interventional endoscopic therapies.

Original languageEnglish
Pages (from-to)2521-2530
Number of pages10
JournalWorld Journal of Gastroenterology
Volume27
Issue number20
DOIs
StatePublished - 28 May 2021

Bibliographical note

Funding Information:
Rubin DT has received grant support from Takeda; and has served as a consultant for Abbvie, Altrubio, Allergan Inc., Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Connect BioPharma, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Materia Prima, Pfizer, Prometheus Biosciences, Reistone, Takeda, and Techlab Inc. Quera R and Nuñez F Phave received support for attending meetings from Janssen.

Publisher Copyright:
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Keywords

  • Crohn's disease
  • Endoscopy
  • Inflammatory bowel disease
  • Surveillance
  • Therapeutic endoscopy
  • Ulcerative colitis

Fingerprint

Dive into the research topics of 'Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis'. Together they form a unique fingerprint.

Cite this